ProQR Therapeutics (PRQR) Operating Leases (2021 - 2025)

ProQR Therapeutics' Operating Leases history spans 4 years, with the latest figure at $11.8 million for Q4 2024.

  • For Q4 2024, Operating Leases fell 20.51% year-over-year to $11.8 million; the TTM value through Dec 2024 reached $11.8 million, down 20.51%, while the annual FY2024 figure was $12.0 million, 19.92% down from the prior year.
  • Operating Leases for Q4 2024 was $11.8 million at ProQR Therapeutics, down from $14.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $16.9 million in Q4 2021 and bottomed at $11.8 million in Q4 2024.
  • The 4-year median for Operating Leases is $14.5 million (2022), against an average of $14.4 million.
  • The largest annual shift saw Operating Leases grew 5.57% in 2023 before it decreased 20.51% in 2024.
  • A 4-year view of Operating Leases shows it stood at $16.9 million in 2021, then decreased by 16.47% to $14.1 million in 2022, then rose by 5.57% to $14.9 million in 2023, then fell by 20.51% to $11.8 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Operating Leases are $11.8 million (Q4 2024), $14.9 million (Q4 2023), and $14.1 million (Q4 2022).